KRAS and RASopathy: Thus, targeting the regulation of transcription through stabilized G4 structures by small molecules and targeted PPRH oligonucleotides that selectively inhibit transcription of KRAS will have great potential in ultimately achieving clinical activity in patients whose tumors have dysregulated KRAS function, such as addicted cancers and RASopathies.